Clinical significance of lymphatic invasion in the esophageal region in patients with adenocarcinoma of the esophagogastric junction.
esophagogastric junction cancer
lymphatic invasion
mediastinal lymph node metastases
survival outcomes
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
01
10
2019
revised:
05
04
2020
accepted:
21
04
2020
pubmed:
3
5
2020
medline:
20
8
2020
entrez:
3
5
2020
Statut:
ppublish
Résumé
The lymphatic flow around the esophagogastric junction is complicated. Therefore, it is unclear whether lymphatic invasion in the esophageal region (eLI) and in the gastric region (gLI) in patients with adenocarcinoma of the esophagogastric junction (AEG) equally affect the incidence of lymph node metastases (LNM), and consequently, survival. We retrospectively reviewed clinicopathological data of 175 patients with AEG between January 2008 and July 2017. Risk factors for LNM and impacts of eLI or gLI on survival outcomes were investigated. eLI was identified in 34% of the patients (59/175). By multivariate analysis, eLI was associated with an increased risk of both mediastinal LNM (odds ratio [OR] = 2.98, 95% confidence interval [CI]: 1.26-7.05) and abdominal LNM (OR = 5.44, 95% CI: 1.95-15.20). The 5-year overall survival for patients with eLI (53%) was significantly worse than for patients without eLI (76%) (hazard ratio = 2.45, 95% CI: 1.37-10.01). gLI was not selected in either of these analyses. Positive eLI was strongly associated with mediastinal and abdominal LNM and worse survival in patients with AEG compared with gLI. In the histopathological examination, it seems to make sense to assess eLI and gLI separately.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The lymphatic flow around the esophagogastric junction is complicated. Therefore, it is unclear whether lymphatic invasion in the esophageal region (eLI) and in the gastric region (gLI) in patients with adenocarcinoma of the esophagogastric junction (AEG) equally affect the incidence of lymph node metastases (LNM), and consequently, survival.
METHODS
METHODS
We retrospectively reviewed clinicopathological data of 175 patients with AEG between January 2008 and July 2017. Risk factors for LNM and impacts of eLI or gLI on survival outcomes were investigated.
RESULTS
RESULTS
eLI was identified in 34% of the patients (59/175). By multivariate analysis, eLI was associated with an increased risk of both mediastinal LNM (odds ratio [OR] = 2.98, 95% confidence interval [CI]: 1.26-7.05) and abdominal LNM (OR = 5.44, 95% CI: 1.95-15.20). The 5-year overall survival for patients with eLI (53%) was significantly worse than for patients without eLI (76%) (hazard ratio = 2.45, 95% CI: 1.37-10.01). gLI was not selected in either of these analyses.
CONCLUSIONS
CONCLUSIONS
Positive eLI was strongly associated with mediastinal and abdominal LNM and worse survival in patients with AEG compared with gLI. In the histopathological examination, it seems to make sense to assess eLI and gLI separately.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
433-441Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Kusano C, Gotoda T, Khor CJ, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23(11):1662-1665. https://doi.org/10.1111/j.1440-1746.2008.05572.x
Yamashita H, Seto Y, Sano T, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(suppl 1):69-83. https://doi.org/10.1007/s10120-016-0663-8
Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3-9. https://doi.org/10.1016/j.semradonc.2012.09.008
Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232-248. https://doi.org/10.1002/caac.21185
Edgren G, Adami HO, Vainio EW, Nyrén O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62(10):1406-1414. https://doi.org/10.1136/gutjnl-2012-302412
Aikou T, Shimazu H. Difference in main lymphatic pathways from the lower esophagus and gastric cardia. Jpn J Surg. 1989;19(3):290-295. https://doi.org/10.1007/BF02471404
Liang P, Nakada I, Hong JW, et al. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: its impact on prognosis. Ann Surg Oncol. 2007;14(2):470-477. https://doi.org/10.1245/s10434-006-9189-3
Barresi V, Reggiani Bonetti L, Vitarelli E, Di Gregorio C, Ponz de Leon M, Barresi G. Immunohistochemical assessment of lymphovascular invasion in stage I colorectal carcinoma: prognostic relevance and correlation with nodal micrometastases. Am J Surg Pathol. 2012;36(1):66-72. https://doi.org/10.1097/PAS.0b013e31822d3008
Hyung WJ, Lee JH, Choi SH, Min JS, Noh SH. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol. 2002;9(6):562-567. https://doi.org/10.1245/aso.2002.9.6.562
Ichikawa D, Kubota T, Kikuchi S, et al. Prognostic impact of lymphatic invasion in patients with node-negative gastric cancer. J Surg Oncol. 2009;100(2):111-114. https://doi.org/10.1002/jso.21311
Kunisaki C, Makino H, Kimura J, et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery. 2010;147(2):204-211. https://doi.org/10.1016/j.surg.2009.08.012
Du CY, Chen JG, Zhou Y, et al. Impact of lymphatic and/or blood vessel invasion in stage II gastric cancer. World J Gastroenterol. 2012;18(27):3610-3616. https://doi.org/10.3748/wjg.v18.i27.3610
Lee JH, Kim MG, Jung MS, Kwon SJ. Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg. 2015;39(3):732-739. https://doi.org/10.1007/s00268-014-2846-y
Brücher BLDM, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer. 2001;92(8):2228-2233. https://doi.org/10.1002/1097-0142(20011015)92:8<2228::AID-CNCR1567>3.0.CO;2-4
Cen P, Hofstetter WL, Correa AM, et al. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008;112(5):1020-1027. https://doi.org/10.1002/cncr.23265
vonRahden BHA, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2005;23(4):874-879. https://doi.org/10.1200/JCO.2005.12.151
Perry C, Soomro I, Kaye P, et al. Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication. Dis Esophagus. 2015;28(3):262-268. https://doi.org/10.1111/dote.12190
Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 7th ed. Hoboken, NJ: Wiley; 2011.
Sano T, Kodera Y. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101-112. https://doi.org/10.1007/s10120-011-0041-5
Kikuchi E, Margulis V, Karakiewicz PI, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009;27(4):612-618. https://doi.org/10.1200/JCO.2008.17.2361
Kurokawa Y, Hiki N, Yoshikawa T, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157(3):551-555. https://doi.org/10.1016/j.surg.2014.08.099
Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254(2):274-280. https://doi.org/10.1097/SLA.0b013e3182263911
Goto H, Tokunaga M, Miki Y, et al. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients. Gastric Cancer. 2015;18(2):375-381. https://doi.org/10.1007/s10120-014-0364-0
Peng J, Wang W-P, Yuan Y, Hu Y, Wang Y, Chen L-Q. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction adenocarcinoma. Ann Thorac Surg. 2015;100(1):263-269. https://doi.org/10.1016/j.athoracsur.2015.02.075
Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644-651. https://doi.org/10.1016/S1470-2045(06)70766-5
Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors [published online ahead of print August 8, 2019]. Ann Surg. https://doi.org/10.1097/sla.0000000000003499